BACKGROUND: It has not been established whether control conditions with large weight losses (WLs) diminish expected treatment effects in WL or prevention of weight gain (PWG)-randomized controlled trials (RCTs). SUBJECTS/METHODS: We performed a meta-analysis of 239 WL/PWG RCTs that include a control group and at least one treatment group. A maximum likelihood meta-analysis framework was used to model and understand the relationship between treatment effects and control group outcomes. RESULTS: Under the informed model, an increase in control group WL of 1 kg corresponds with an expected shrinkage of the treatment effect by 0.309 kg (95% confidence interval (−0.480, − 0.138), P = 0.00081); this result is robust against violations of the model assumptions. CONCLUSIONS: We find that control conditions with large WLs diminish expected treatment effects. Our investigation may be helpful to clinicians as they design future WL/PWG studies.
INTRODUCTION
Investigators planning an obesity-randomized controlled trial (RCT) of drugs, dietary supplements or other treatments must ask themselves: 'How intense should we make the intervention provided to the control group and the treatment group in addition to the treatment to be tested?' This is related to but distinct from the debate about placebo vs active controls 1 and concerns the background intervention, the intervention that both the control group and the treatment group receive in addition to the treatment to be tested. On the one hand, some individuals advocate using the minimum background intervention that is ethically acceptable, such as providing a pamphlet on good weight loss (WL) practices. The rationale is twofold: (i) It is suggested that this approach better emulates the real-life conditions under which people will receive the treatment; and (ii) some investigators may wish to observe the maximum change the treatment can achieve and are concerned that giving too vigorous a background intervention will cause the estimated treatment effect (the mean difference in outcome, such as WL or prevention of weight gain (PWG), between the control and treatment groups) to be diminished. On the other hand, others advocate using the maximum background intervention that is practical, such as providing a vigorous program of diet and exercise supported by intensive counseling. The rationale for this is also several fold: (c) it is suggested that this approach may be more clinically sound because it assesses the incremental effect of a (presumably) riskier second-line intervention on top of a (presumably) more accepted and benign first-line intervention; (d) Those that hope to subsequently see the studied treatment be widely adopted, in addition to wishing to report a large treatment effect, wish to report the largest possible mean WL in the treatment group. That is, the statement 'Patients receiving X treatment lost an average of Y kgs' is more compelling when Y is large; and (e) clinicians, investigators and regulators often wish to evaluate the best performance that the treatment can achieve and it is presumed that by coupling it with the most vigorous background intervention possible, this will produce the greatest overall effect.
The focus of this review, however, is not on the relative merits of specific types of background interventions (for example, providing only a weight loss pamphlet) but rather on the sequelae from choosing a relatively weak or strong background intervention, namely the amount of WL in the control group, how much this differs from that of the intervention group (that is, the treatment effect), and their relationship. Information about this relationship is needed if informed decisions are to be made about the relative merits of strong vs weak background interventions, as well as considerations in power analyses and sample size calculations. Yet, after a careful search of the literature and discussion with colleagues in the field, we have been unable to identify any published or unpublished analyses that provide information about the relation between the true mean change in control group outcome and treatment effect, when considering the broader population of WL/PWG RCTs. It is tempting to try to answer whether there is an association between these values using standard statistical approaches such as ordinary linear regression or correlation coefficients. However, as explained by Schmid et al. 2 and McIntosh, 3 such simple approaches are likely biased and a different approach is required. Herein, we address this question by performing a meta-analysis of WL/PWG RCTs and discuss the implications of its results with respect to the qualitative choice of the background intervention and its potential consequences.
MATERIALS AND METHODS
This meta-analysis was performed as a secondary analysis to another investigation; 4 as it uses publically available summary data, these projects received a certificate of exemption from the University of Alabama at Birmingham Institutional Review Board in accordance with the Common Rule. The review criteria here are slightly changed from that previous investigation, so we provide the relevant details below.
Article search criteria and retrieval Articles, abstracts and doctoral dissertations were retrieved using searches performed on electronic databases: PubMed, Cochrane Library, ISI Web of Science, PsycINFO and CINAHL (Cumulative Index to Nursing and Allied Health Literature) and Dissertation Abstracts.
PubMed was searched with and without MeSH headings to identify publications for inclusion, using the following limits: publication date, RCTs and human studies.
Article selection criteria All studies were evaluated according to the following inclusion criteria:
1. The data were from human studies. 2. The study was a RCT. 3. The study had a total sample size of at least 30 participants at enrollment. 4. The study protocol included an intervention period of at least 8 weeks. 5. WL and/or PWG was a primary or secondary outcome variable. 6. The publication was available in the English language. 7. The study was published between 1 January 2007 and 1
July 2009.
The above provided an initial pool of 317 WL/PWG RCTs in adults for meta-analysis. However, this analysis also has the following exclusion criterion:
1. The study could not be a purely head-to-head comparison of two or more experimental treatments (that is, no real control group)
This criterion excluded 78 studies from the initial pool, so that the 239 remaining studies are all experiments that compare a control group of some kind with one or more treatment groups; information regarding these studies may be found in the Supplementary Materials. The nature of the control groups varied in scope from those that were not given a treatment (for example, the control group consisted of patients on a wait list) to those that received the standard of care alternative to some experimental drug. Of the 239 trials, 80 had more than a single treatment arm; within these the number of study arms ranged from 3 to 8.
Statistical model
In all of the studies under consideration, the observed control group and treatment group WLs (and hence the observed treatment effect) have some error associated with them, as they are based on random samples and therefore we should not naively treat them as substitutes for the true values of those quantities, either within studies or across the population of studies. Thus, to interrogate the relationship between namely the amount of WL in the control group and how much this differs from that of the intervention group, we apply the model provided by McIntosh, 3 which assumes that true (population-level) WL in the i th study's control arm (θ C i ) and the treatment effect (Δ i ) are related thusly
where β* is one less than the 'structural slope'. To clarify this point, the original model provided by McIntosh is equivalent to the one given by EQ1 but the original model is parameterized in terms of the control WL and the treatment WL, rather than the control WL and the treatment effect; since we are interested in the latter, this parameterization with β* is more informative. This model allows for the within-study treatment effect Δ i to deviate from the population-level treatment effect (μ E − μ C , where μ E is the average treatment group WL across studies and μ C is the average control group WL across studies) in response to a divergence of the control arm WL θ C i from μ C , and the nature of that deviation is determined by β*; see Figure 1 . For a concise summary of the possible clinical interpretations of β*, depending on its value, see Table 1 ; by estimating β*, we estimate the relationship between the intensity of the background intervention and the expected treatment effect. Estimates for quantities of interest were derived via an expectation-maximization (EM) algorithm 5 as described by McIntosh 3 (see pp. 1718-9) with s.e. for the EM estimates obtained via a supplemented EM (s.e.m. 6, 7 ).
Statistical adjustments and considerations
It is the case that 80 of our studies have 42 study arms. However, the model presented in the previous section assumes that all studies have exactly two arms: a treatment group and a control group. In addition, the model assumes that the group WL variances are known quantities. We address these discrepancies by treating a K-arm study as (K-1) two-arm studies, with the same control group values and using the study-derived estimates of the group WL variances as the true values. Both of these choices are violations of the model's inherent assumptions and we present sensitivity analyses that assess their impact. In addition, missing data exist for both means and s.d. of weight change within study arms. 4 Thus, we performed multiple imputation using SPSS version 20 (ref. 8) and a total of 30 imputations. Correspondingly, the point estimates and measures Figure 1 . An illustration of the relationship between β* and expected treatment effect using data simulated under the structural model. In the figure, simulated treatment group means are plotted on the y-axis against control group means on the x-axis, using β* = − 0.309; γ represents an arbitrary offset. Since β* is in (−1,0) , larger control group means are associated with smaller treatment effects Δ i (represented by the lengths of the vertical segments) on average.
of their uncertainty will reflect a pooling over these imputations 
RESULTS
Meta-analysis of our WL/PWG studies indicates that the maximum likelihood estimate for β* is − 0.309 and the corresponding 95% confidence interval 95% CI is (−0.480, − 0.138). The probability of observing an estimate of β* at least this far from 0 when β* is 0 is 0.00081. Therefore, we conclude that β* falls within (−1, 0) and hence increases in control group WL are associated with corresponding decreases in treatment effect. This and other computed quantities, such as the population variance of the control groups across the population of studies, may be found in Table 2 . Our finding for β* has several clinical ramifications, which we will discuss presently after providing some sensitivity analyses in the next section to assess the robustness of our results in light of known model violations.
Sensitivity analyses
We conducted three sensitivity analyses to assess the robustness of our results against known violations of the model assumptions. First, our treatment of studies with multiple treatment arms violates the assumption of independence and identical distribution in EQ1. To examine its potential effects, we reran the analysis one thousand times, using only one treatment arm chosen at random per study. In none of the thousand iterations of this procedure does the 95% CI for β* cross either − 1 (all lower bounds greater than − 0.56) or 0 (all upper bounds lower than − 0.09).
Second, to gauge the potential effects of using sample variances as true variances, we reran the analysis using moderated variances: sample variances were replaced by weighted averages of the sample estimate and the median of all variances in that arm type (control or treatment), with weights by sample size compared with the median sample size. After doing so, the maximum likelihood estimate for β* is − 0.343 and the corresponding 95% CI is (−0.504, − 0.181).
Last, we checked to see if the presence of a few very large studies unduly influenced our results by removing any of our twoarm studies with sample size 4600; 600 roughly corresponds to the upper 4% of the observed distribution of sample sizes and was chosen because it resides in the largest gap between observed sample sizes on the high end (neighbored by 566 and 707); 14 studies are 'large' according to this criterion. Under this restriction, the maximum likelihood estimate for β* is − 0.319 and the corresponding 95% CI is (−0.486, − 0.151).
We conclude that our analysis is robust against the violations of model assumptions incurred by our specific approach.
DISCUSSION
While all values of β* in (−1,0) can be qualitatively described in the same manner, the degree to which increases in control group WL shrink the expected treatment effect depend on the magnitude of β*. Under the informed model, for every kilogram by which the control group population mean WL increased, the treatment effect is on average reduced by about 0.3 kg. So, for example, if there are two WL RCTs that have control group WLs equal to 1 kg and 5 kg, respectively, our meta-analysis predicts expected treatment group WLs of 3.1 kg and 5.9 kg, which correspond to expected treatment effects of 2.1 kg and 0.9 kg, respectively.
Prima facie, the importance of this result that more rigorous background interventions do 'steal' some efficacy from the studied treatment might not be obvious. However, it has several direct impacts in the planning and execution of WL/PWG RCTs. First, use of strong background interventions are associated with smaller-than-expected treatment effects; even taking the suppositions of rationales c-e from the introduction as truth, governmental regulatory bodies are first and foremost interested in seeing statistically significant and clinically meaningful treatment effects, as opposed to merely large WLs among subjects in the intervention arm; indeed, according to the FDA guidance for WL RCTs, 10 the only two primary efficacy endpoints that merit consideration are 'the difference in mean percent loss of baseline 
Increasing control group weight loss (WL) θ C i is associated with shrinking treatment group WL θ E i . This scenario is unlikely in our setting as both WL groups receive a common background intervention in every study and hence are expected to be positively correlated. β* = − 1 θ C i and θ E i are uncorrelated. This scenario is also unlikely due to a common background intervention in every study. β* is in (−1, 0) Increasing θ C i is associated with increasing θ E i , but at a slower rate than θ C i ; thus, increasing θ C i is associated with shrinking treatment effect Δ i . See Figure 1 for an illustration of this scenario. β* = 0 θ C i and Δ i are uncorrelated. Hence the expected treatment effect is constant and equal to Δ for all values of θ C i . β*40
Increasing θ C i is associated with increasing Δ i Abbreviations: CI, confidence interval; df, degree of freedom. This table contains quantities related to the parameters of the structural model. μ E and μ C correspond to the true average weight loss across treatment and control arms, respectively, in kgs. ν C is the population-level variance for true weight loss means in the control arms across studies and ν E is the residual variance; see equation (1) . β* is one less than to the structural slope; see Table 1 for its interpretation.
body weight in the active-product vs placebo-treated group' or 'the proportion of subjects who lose at least 5% of baseline body weight in the active-product vs placebo-treated group'. If it cannot be shown that one of these primary endpoints has a statistically significant and clinically meaningful treatment effect, the investigational product is simply nonviable. Second, providing an estimate of the expected reduction in treatment effect given the amount of control WL allows researchers to better a priori estimate the treatment effects that they might see in their WL/PWG RCTs, so that these studies will have sufficient sample size to be adequately powered. Considering that only modest WLs were observed in these published RCTs (as the reader may see in Table 2 , the average treatment effect was only a little more than 2 kg), regardless of the observed differences in rigor of control interventions, researchers simply cannot rely on large effect sizes to power studies. As the reader may also note from Table 2 , there is considerable variation about the estimates of the treatment effects given the control WLs, so our guideposts should perhaps be treated only as a conservative measure of what kind of attenuations of treatment effect might be seen in practice, just to be safe. Third and last, knowing what kinds of treatment effects to expect will help provide meaningful informed consent among subjects undergoing WL/PWG RCTs, considering that roughly half of subjects would not countenance even a single percentage point chance of a serious adverse event when expecting only modest (5-10%) WL.
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Some of the strengths of this analysis include the very large sample size of RCTs utilized to derive the estimates. In addition, very rigorous methods were used to select studies, extract the data and assure completeness and accuracy of the dataset; for example, three rounds of inter-rater reliability were performed when assessing study characteristics and data, to ensure agreement ⩾ 80%. 4 While some differences in adjusted WL may be observed between different types of interventions (for example, diet plus exercise typically having a greater effect on WL vs exercise alone), the range of effects outside of bariatric surgery (not included in this analysis) is not large. Some limitations of the present analysis are due to potential issues in the studies that inform it and include combined gender analyses, the inclusion of diabetic and insulin-resistant patient samples and the possibility that measures of baseline body composition such as BMI and percent body fat were not comparable across control and treatment groups. Related in part to this last point, the quantity β* reflects the association between the treatment effect and divergences of the observed control mean from the average control mean across studies. While we feel it is reasonable to assume that these divergences are primarily being driven in differences in the background intervention across studies, it is also possible that the values of the divergences may be affected by differences in population-specific risk factors which may (such as age or gender) or may not (such as BMI or some 'unknown unknown') have been recorded. However, since those differences might strengthen or weaken the divergences across studies in a manner independent of the background intervention, it is our belief that they should only add to the variability of the control means marginally without biasing them.
Analysis of more homogeneous sub-populations may show different estimates. However, these types of participants and targeted populations are representative of the present day status of overweight and obese persons that are typically recruited for obesity RCTs. One of the major barriers to our sample size was the degree of data not reported and/or not available in public repositories or from author contacts. We employed multiple imputation and sensitivity analyses to address these limitations.
In conclusion, our results confirm the intuition of some investigators that more rigorous background interventions do 'steal' some efficacy from the studied treatment. For every kilogram by which the control group population mean WL increased, the treatment effect is reduced by about 0.3 kg. This recognition allows researchers to obtain more accurate estimates of treatment effects a priori, to design adequately powered investigations that will have a greater chance of gaining regulatory approval.
